Please login to the form below

Not currently logged in
Email:
Password:

Multipharma launches Inceptua Medicines Access

The group will be split into three sub-divisions

InceptuaMultipharma has launched Inceptua Medicines Access, a speciality business unit that offers access to pre-approval and unlicensed medicines.

The Luxembourg-based drug sourcing group’s new business will be split into three divisions that cover pre-approval access programmes, sourcing and supplying unlicensed medicines and strategy support services.

Peter Krantz, chief executive officer of Multipharma, said: “The establishment of Inceptua Medicines Access is the logical next step in the expansion of Multipharma, and perfectly complements the existing services supporting clinical trials of comparator sourcing, strategic planning, global depot solutions and clinical manufacturing.

“With this new addition Multipharma is poised to become a major global provider in the clinical trial services, pre-approval and unlicensed medicines space.”

All Inceptua three divisions will harness “state-of-the-art technologies” seeks to deliver medicines and investigational treatments to patients in areas that lack these facilities.

Mark Corbett, executive vice president of Inceptua Medicines Access, said: “The sector has not adapted nor kept pace with the needs of the biopharmaceutical industry, healthcare professionals and their patients worldwide.

“Current demand combined with a complex and dynamic regulatory and political landscape means we need a new way of thinking about ethical and compliant access to pre-approval and unlicensed medicines.

“We want to provide our clients and customers with a best-in-class service that makes us the go-to global provider for pre-approval and unlicensed medicines.”

Article by
Gemma Jones

16th June 2017

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...